Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Hologic ( (HOLX) ).
On September 18, 2025, Hologic, Inc. announced an amendment to the employment agreement with its CEO, Stephen P. MacMillan, extending the term of the agreement. This extension reflects the company’s commitment to stable leadership, potentially impacting its strategic direction and reassuring stakeholders of continued executive oversight.
The most recent analyst rating on (HOLX) stock is a Hold with a $72.00 price target. To see the full list of analyst forecasts on Hologic stock, see the HOLX Stock Forecast page.
Spark’s Take on HOLX Stock
According to Spark, TipRanks’ AI Analyst, HOLX is a Neutral.
Hologic’s overall stock score reflects a stable financial position with strong revenue growth, though profitability and cash flow growth need improvement. The positive sentiment from the earnings call and strategic initiatives provide a favorable outlook. However, the high valuation and mixed technical indicators suggest caution.
To see Spark’s full report on HOLX stock, click here.
More about Hologic
Hologic, Inc. operates in the medical technology industry, focusing on developing and providing diagnostic products, medical imaging systems, and surgical products, primarily for women’s health.
Average Trading Volume: 1,961,614
Technical Sentiment Signal: Buy
Current Market Cap: $15.17B
Learn more about HOLX stock on TipRanks’ Stock Analysis page.